Part of GSK Plc, Beecham Group Plc is a British company located in Middlesex. The firm functions as an investment holding company. It was founded in 1928.\nThe company says this about itself: The principal activity Of the Company is the holding of Intercompany bans and receipt Of interest. The Company had previously been an investment holding company. The Company is a member Of the GlaxoSmithKline Group (the 'Group\"). The directors do not envisage any change to the nature of the business in the future,

Mutabilis SA specializes in the discovery and development of anti-infective drugs. It focuses on novel therapeutic approaches for controlling severe and nosocomial infections. The firm offers antibacterial, vaccines, anti-infective agents, gram-positive & negative ant virulence lead series, specific antigens, and screening technologies for antibacterial and virulence targets. The company was founded in 2001 by Xavier Nassif and is headquartered in Romainville, France.

Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Entasis Therapeutics Ltd., part of Innoviva, Inc., is a British company located in Altrincham that manufactures and distributes pharmaceutical products. It was founded in 2015.

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options.

Meiji Seika Pharma Co., Ltd. engages in the business of manufacture and distribution of pharmaceutical products. It also engages in the animal health business. The company was founded on October 9, 1916 and is headquartered in Tokyo, Japan.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France

Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.

Merck Sharp & Dohme LLC, part of Merck & Co., Inc., is a company headquartered in Kenilworth, NJ, that operates as a pharmaceutical company.

Part of Pfizer Inc., Wyeth Lederle Japan Ltd is a company headquartered in Tokyo, Japan, specializing in pharmaceutical preparations. Wyeth Corp., now a subsidiary of Pfizer Inc. acquired Wyeth Lederle Japan Ltd from Takeda Pharmaceutical Co., Ltd. on May 21, 2003.

Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases. It develops multiple antibiotic drugs intended to combat antimicrobial resistance. The company's technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases, deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance, enabling medical businesses optimal use of products and critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. It was founded in 2018 and is headquartered in San Diego, California.

Part of Sihuan Pharmaceutical Holdings Group Ltd., Shandong Xuanzhu Pharmaceutical Technology Co., Ltd. is a company headquartered in China. The firm engages in the research, development and sale of pharmaceutical products.

Sandoz AG, part of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Otsuka Chemical Co., Ltd. engages in the production of chemicals and diet supplements. It provides inorganic salts, bromides, hydrazine, foaming agent, polymerization initiator, preparation articles, rust-preventive agent, fire retarding material, intermediates, and electro-organic synthesis products. The company was founded on August 29, 1950 and is headquartered in Tokyo, Japan.

Showa Yakuhin Kako Co., Ltd. engages in the manufacture and sale of pharmaceuticals, medical devices, and quasi-drugs. It operates through the following business divisions: Pharmaceutical Business and Dental Business. The Pharmaceutical Business division develops and produces generic drugs, and antipyretic analgesics. The Dental Business division supplies dental anesthetics and agents for dental and oral use. The firm also produces non-pharmaceutical supplies, medical equipment, and reagents. Its products include ORA injection, Perifeel and Hinoporon. The company was founded in July 1948 and is headquartered in Tokyo, Japan.

Nanjing Mingde New Drug Research and Development Co., Ltd., established on 2011-12-16, The scope of business includes engaging in pharmaceutical,Biological product,medical instruments,food development,Research;Environmental and pesticide testing services;Pharmaceutical Small Molecule Compound Library,Preclinical studies of drug leads and drug products,Technology development related to process development and clinical research,Technology introduction,Technical Services,Technical consulting and technology transfer,related technology,Licensing of Patents and Intellectual Property,Achievement Transformation and Transfer;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval)